Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal toxicity which may result in treatment discontinuation. Assuming that a lower single dose of c...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 April 2016
|
| In: |
BMC cancer
Year: 2016, Volume: 16 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-016-2289-y |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s12885-016-2289-y
|
| Author Notes: | K. Lisenko, F. McClanahan, T. Schöning, M.A. Schwarzbich, M. Cremer, T. Dittrich, A. D. Ho and M. Witzens-Harig |
| Summary: | Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal toxicity which may result in treatment discontinuation. Assuming that a lower single dose of cisplatin over several days would reduce renal toxicity, our institution has chosen to administer cisplatin in a dosage of 25 mg/m2 per day as a 3-h infusion over 4 consecutive days. |
|---|---|
| Item Description: | Gesehen am 08.11.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-016-2289-y |